Indian Pharma Market registers 7.2 percent growth in October: AIOCD-AWACS Report

The industry sales rose as 7.2 percent (in terms of Value) at Rs 15338 crore in October compared to the same month in 2021. That compares with a 5.5 percent year-on-year increase in October 2021 and 13% growth in September 2022.

The Moving Annual Total (MAT) or 12-month rolling sales of overall pharma products rose 6.4 percent at Rs 176671 crore in October.

As per the All India Organization of Chemists and Druggists' (AIOCD-AWACS) market research, among the top therapies, Cardiac, Derma, Respiratory and Gynaec have shown a robust value growth. Anti-infectives is the only therapy among the top therapies that has shown value degrowth of -7.9 percent valued at Rs 22011 crore.

Quarterly Growth Driver QTR trend showed volumes fell 0.9% year-on-year. New product launches registered 1.8% growth, while prices increased by 6.3%.

Overall, the acute-therapy segment grew 5.3% year-on-year, compared to 8.1% growth in October 2021, the AIOCD data cited.

Further, chronic therapy, which comprises medicines for long-term ailments such as cardiac ailments and diabetes, and the sub-chronic segment saw growth of around 8.8% and 8.7%, respectively. That compares to 1.9% and 2.9% growth in October 2021.

Sales of gynecological products rose the most by 16.4%, followed by an 11.8% growth in the dermatological segment and a 10.6% growth in the respiratory segment.

Cardiac segments grew by 9.8%, followed by pain, neurological/CNS segments, and vitamins in the range of 7%–8%.

Gastroenterology and anti-diabetic segments grew 5.6% and 5%, respectively, over the year-ago period, while sales of anti-infectives declined 1.2%.

Also Read: Indian Pharma Market Sees 12.1 Percent Growth In August: AIOCD-AWACS Report

In terms of monthly sales, Sun Pharma + Ranbaxy topped the top 20 Corporates list with growth of 8.55 percent at Rs 1250 crore followed by Abbott + Abbott HC + Novo and Cipla with a growth of 6.49% and 5.01% respectively.

Meanwhile, the top three selling brands in India in October were Manforce manufactured by Mankind Pharma; Augmentin, commonly used to treat infections of the urinary tract, respiratory tract, ear, sinuses, and skin, marketed by GSK and Foracort by Cipla.